ランセット・オンコロジーに載ったコメント

Outcomes for girls without HPV vaccination in Japan

Volume 17, No. 7, p868–869, July 2016

Yusuke Tanaka,Yutaka Ueda,Tomomi Egawa-Takata,Asami Yagi,Kiyoshi Yoshino,Tadashi Kimura

 

大阪大学医学部産婦人科

上田豊、木村 正　他

要旨

In Japan, HPV vaccinations became available to girls aged 13–16 years with public aid from 2010 and subsequently became routine for those aged 12–16 years from April, 2013. However, in the spring late spring of 2013, the media repeatedly reported adverse events which were attributed to the HPV vaccination (including pain and motor disability) even though it is not exactly known whether these effects were actually caused by the vaccine. The Japanese Ministry of Health, Labour, and Welfare suspended its active recommendation for girls to receive HPV vaccinations in June, 2013.

利益相反の開示

Coauthors Yutaka Ueda and Tadashi Kimura received lecture fees from GlaxoSmithKline/Japan Vaccine (the manufacturer of the HPV vaccine Cervarix). Dr Ueda also received a lecture fee, research fund, and consultation fee from Merck Sharp & Dohme (the manufacturer of the HPV vaccine Gardasil) and research funding from the Japan Agency for Medical Research and Development. The other authors have disclosed no relevant financial relationships.

ウエダユタカとキムラタダシは、グラクソスミスクライン・ジャパンワクチン（サーバリックスの製造元）から講演料を受け取った

ドクターウエダは、メルク社（ガーダシルの製造元）からも、講演料、研究基金、コンサルタント料を、日本医療研究開発機構から研究基金を受け取った

他の著者らは、関連する金銭上の関係はない